Myocardial dysfunction in mitochondrial diabetes treated with Coenzyme Q10

Diabetes Res Clin Pract. 2006 Apr;72(1):100-3. doi: 10.1016/j.diabres.2005.09.005. Epub 2005 Oct 25.

Abstract

Maternally-inherited diabetes and deafness (MIDD) has been related to an A to G transition in the mitochondrial tRNA Leu (UUR) gene at the base pair 3243. Although some previous articles have reported that this mutation may be a cause of cardiomyopathy in diabetes, the degree of cardiac involvement and a specific treatment has not been established. Here, we reported a case of a patient with MIDD who developed congestive heart failure and the therapeutic usefulness of Coenzyme Q10 (CoQ10). In our patient, after the introduction of Coenzyme Q10 150 mg/day, there was a gradual improvement on left ventricular function evaluated by echocardiography. The fractional shortening (FS) and ejection fraction (EF) increased from 26 to 34% and from 49 to 64%, respectively. No side effects were noted. Three months after CoQ10 discontinuation, the parameters of systolic function evaluated by echocardiography decreased, suggesting that CoQ10 had a beneficial effect. Identification of diabetes and cardiomyopathy due to mitochondrial gene mutation may have therapeutic implications and Coenzyme Q10 is a possible adjunctive treatment in such patients.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antioxidants / therapeutic use
  • Coenzymes
  • DNA, Mitochondrial / genetics
  • Diabetic Ketoacidosis / complications
  • Diabetic Ketoacidosis / drug therapy*
  • Female
  • Heart / physiopathology*
  • Heart Function Tests
  • Humans
  • Insulin / therapeutic use
  • Mutation, Missense
  • RNA, Transfer, Leu / genetics
  • Ubiquinone / analogs & derivatives*
  • Ubiquinone / therapeutic use
  • Wolff-Parkinson-White Syndrome / complications

Substances

  • Antioxidants
  • Coenzymes
  • DNA, Mitochondrial
  • Insulin
  • RNA, Transfer, Leu
  • Ubiquinone
  • coenzyme Q10